Michael J Haller, M.D.

Hello! My name is Dr. Haller but my patients call me Dr. Mike. I work as a Professor and Chief of Pediatric Endocrinology at the University of Florida. As a Gainesville native, and the child of two teachers, I was exposed from an early age to the many incredible educational opportunities afforded by our diverse and highly educated city. My early interests in biology and chemistry combined with my desire to help people and work with children led me pretty directly towards pursuing a career in pediatrics. My interest in pediatric endocrinology was shaped by my grandfather’s experience living with diabetes, experiences volunteering at the Florida Diabetes Camps, and exceptional mentoring from Drs. Desmond Schatz, Janet Silverstein and Mark Atkinson.

I have been involved in type 1 diabetes research since the early 1990s and have published over 200 manuscripts and more than 20 reviews/book chapters on type 1 diabetes pathogenesis, prevention, and interdiction. I am the principal investigator or co-investigator on numerous JDRF, NIH, and Helmsley trust funded studies. My goal is to work every day to improve the lives of children and families affected by type 1 diabetes. I am hopeful that during my career we will develop therapies that can meaningfully prevent and reverse type 1 diabetes.

In my free time, I enjoy spending time with my wife, Dr. Allison Haller (an Anesthesiologist and also a Gator Med School Grad), our 2 children, and our dogs. I also love to spend time in nature, watch live music, attend Gator sporting events, and fly planes.

Dr. Haller’s research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.